Delphine Réa

19.8k total citations · 3 hit papers
224 papers, 8.2k citations indexed

About

Delphine Réa is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Delphine Réa has authored 224 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 199 papers in Hematology, 142 papers in Genetics and 66 papers in Rheumatology. Recurrent topics in Delphine Réa's work include Chronic Myeloid Leukemia Treatments (186 papers), Chronic Lymphocytic Leukemia Research (125 papers) and Eosinophilic Disorders and Syndromes (66 papers). Delphine Réa is often cited by papers focused on Chronic Myeloid Leukemia Treatments (186 papers), Chronic Lymphocytic Leukemia Research (125 papers) and Eosinophilic Disorders and Syndromes (66 papers). Delphine Réa collaborates with scholars based in France, United States and Germany. Delphine Réa's co-authors include François‐Xavier Mahon, Laurence Legros, François Guilhot, Philippe Rousselot, Gabriel Étienne, Aude Charbonnier, Françoise Huguet, Franck E. Nicolini, Joëlle Guilhot and Josy Reiffers and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Delphine Réa

210 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

2010 1.0k citations François‐Xavier Mahon, Delphine Réa et al. profile →
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

2016 330 citations Massimo Breccia, Valentín García‐Gutiérrez et al. Leukemia profile →
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

2016 315 citations Gabriel Étienne, Delphine Réa et al. profile →

Peers

Countries citing papers authored by Delphine Réa

Since Specialization

Citations

This map shows the geographic impact of Delphine Réa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Delphine Réa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Delphine Réa more than expected).

Fields of papers citing papers by Delphine Réa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Delphine Réa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Delphine Réa. The network helps show where Delphine Réa may publish in the future.

Co-authorship network of co-authors of Delphine Réa

This figure shows the co-authorship network connecting the top 25 collaborators of Delphine Réa. A scholar is included among the top collaborators of Delphine Réa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Delphine Réa. Delphine Réa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A newcomer in allosteric therapy for Ph+ leukemias 2025 ·Blood ·Delphine Réa	0
2	Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results 2025 ·Leukemia ·Jörge E. Cortes, Fabian Lang, Delphine Réa, Andreas Hochhaus, Massimo Breccia, Yeow Tee Goh, Michael C. Heinrich, Timothy P. Hughes, Jeroen J. W. M. Janssen, Philipp le Coutre, Hironobu Minami, Koji Sasaki, Daniel J. DeAngelo, Gessamí Sánchez-Ollé, (unknown), (unknown), Matthias Hoch, Michael J. Mauro	4
3	CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML 2025 ·Blood ·Elias Jabbour, Timothy P. Hughes, Richard Van Etten, David Andorsky, (unknown), Philipp le Coutre, Omer Jamy, Pilar Giraldo, Dong-Wook Kim, Vivian G. Oehler, Andreas Hochhaus, (unknown), Michael J. Mauro, Tonya Marmon, Leanne Holes, Emil Kuriakose, H. Kantarjian, Delphine Réa	0
4	Asciminib and pregnancy in CML: Preliminary human data and clinical implications from 47 reported outcomes 2025 ·Blood ·Elisabetta Abruzzese, Ekaterina Chelysheva, Delphine Réa, Kátia Bórgia Barbosa Pagnano, Mohamed A. Yassin, (unknown), Malgorzata Monika Trawinska, Anna Turkina, Jane F. Apperley, Paolo de Fabritiis	0
5	BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib 2024 ·Blood ·(unknown), Diego Garrido Ruiz, RosaAnna DeFilippis, (unknown), Delphine Réa, (unknown), (unknown), Feifei Hu, (unknown), Yibing Shan, Oliver Hantschel, Matthew P. Jacobson, Neil P. Shah	15
6	Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms 2021 ·Blood ·(unknown), Lin‐Pierre Zhao, Nabih Maslah, Emmanuelle Verger, (unknown), (unknown), Marine Cazaux, Nicolas Gauthier, (unknown), Emmanuelle Clappier, Nathalie Parquet, Christine Dosquet, Delphine Réa, Jean‐Marc Zini, William Vainchenker, Emmanuel Raffoux, Stéphane Giraudier, Jean‐Jacques Kiladjian, Bruno Cassinat, Lina Benajiba	20
7	SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN) 2020 ·Blood ·(unknown), (unknown), (unknown), Juliette Soret, Nicolas Gauthier, Emmanuelle Verger, Nabih Maslah, (unknown), Nathalie Parquet, Christine Dosquet, Delphine Réa, Jean‐Marc Zini, William Vainchenker, Emmanuel Raffoux, Stéphane Giraudier, Bruno Cassinat, Jean‐Jacques Kiladjian, Lina Benajiba	2
8	COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study 2020 ·Blood ·Delphine Réa, Michael J. Mauro, Jörge E. Cortes, Qian Jiang, Kátia Bórgia Barbosa Pagnano, (unknown), Chung Hoow Kok, Nicola Evans, Timothy P. Hughes	16
9	Effects of transdermal flunixin meglumine on experimentally induced lameness in adult dairy cattle 2019 ·Journal of Dairy Science ·Michael D. Kleinhenz, Patrick J. Gorden, Joe S. Smith, Jennifer A. Schleining, Katie E. Kleinhenz, (unknown), Delphine Réa, Johann F. Coetzee	19
10	Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study 2019 ·Leukemia & lymphoma ·Neil P. Shah, Valentín García‐Gutiérrez, Antonio Jiménez‐Velasco, Sarah M. Larson, Susanne Saußele, Delphine Réa, François‐Xavier Mahon, Moshe Levy, María Teresa Gómez‐Casares, Fabrizio Pane, Franck‐Emmanuel Nicolini, Michael J. Mauro, Oumar Sy, Patricia Martin‐Regueira, Jeffrey H. Lipton	97
11	Molecular Responses after Switching from a Standard-Dose Twice-Daily Nilotinib Regimen to a Reduced-Dose Once-Daily Schedule in Patients with Chronic Myeloid Leukemia: A Real Life Observational Study (NILO-RED) 2017 ·Blood ·Delphine Réa, Jean‐Michel Cayuela, Stéphanie Dulucq, Gabriel Étienne	24
12	Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis 2017 ·Journal of Cancer Research and Clinical Oncology ·Andreas Hochhaus, (unknown), Philipp le Coutre, L. N. Petrov, Jeroen J. W. M. Janssen, Nicholas C.P. Cross, Delphine Réa, Fausto Castagnetti, Andrzej Hellmann, Gianantonio Rosti, Norbert Gattermann, (unknown), (unknown), Valentín García‐Gutiérrez, Bruno Vincenzi, Luca Dezzani, Francis J. Giles	6
13	0195: Identification of patients (pts) with chronic myeloid leukemia (CML) at high risk of artery occlusive events (AOE) during treatment with the 2nd generation tyrosine kinase inhibitor (TKI) nilotinib 2015 ·Archives of Cardiovascular Diseases Supplements ·Emmanuel Messas, Tristan Mirault, Emmanuel Raffoux, (unknown), Philippe Rousselot, Hervé Dombret, Delphine Réa	1
14	Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib 2013 ·Leukemia ·(unknown), Delphine Réa, Michaela Schwarz, (unknown), Franck E. Nicolini, Gianantonio Rosti, Luciano Levato, Francis J. Giles, Hervé Dombret, Tristan Mirault, Hélène Labussière, Ruhdja Lindhorst, Wilhelm Haverkamp, Ivo Buschmann, Bernd Dörken, Phillipp D. Le Coutre	171
15	Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation 2012 ·Blood ·Jörge E. Cortes, Jeff H. Lipton, Delphine Réa, Raghunadharao Digumarti, Charles Chuah, Nisha Nanda, (unknown), Adam R. Craig, Mauricette Michallet, Franck E. Nicolini, Hagop M. Kantarjian	89
16	Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study 2012 ·Biology of Blood and Marrow Transplantation ·Aline Schmidt, Philippe Rousselot, Yves Chalandon, Jean‐Michel Cayuela, Sandrine Hayette, Marie‐Christiane Vekemans, Martine Escoffre, Françoise Huguet, Delphine Réa, André Delannoy, Jean‐Yves Cahn, Jean‐Paul Vernant, Norbert Ifrah, Hervé Dombret, Xavier Thomas	106
17	Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia 2007 ·American Journal of Respiratory and Critical Care Medicine ·Anne Bergeron, Delphine Réa, Vincent Lévy, C. Picard, Véronique Meignin, Jérôme Tamburini, Heriberto Bruzzoni‐Giovanelli, Fabien Calvo, Abdellatif Tazi, Philippe Rousselot	116
18	Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years 2006 ·Blood ·Philippe Rousselot, Françoise Huguet, Delphine Réa, Laurence Legros, Jean Michel Cayuela, Odile Maarek, Odile Blanchet, Gérald Marit, Éliane Gluckman, Josy Reiffers, Martine Gardembas, François‐Xavier Mahon, (unknown)	387
19	BCR/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia 2006 ·The Journal of Immunology ·Nicolas Boissel, Delphine Réa, Vannary Tieng, Nicolas Dulphy, Manuel Brun, Jean‐Michel Cayuela, Philippe Rousselot, Ryad Tamouza, Philippe Le Bouteiller, François‐Xavier Mahon, Alexander Steinle, Dominique Charron, Hervé Dombret, Antoine Toubert	118
20	Highly Efficient Transduction of Human Monocyte-Derived Dendritic Cells with Subgroup B Fiber-Modified Adenovirus Vectors Enhances Transgene-Encoded Antigen Presentation to Cytotoxic T Cells 2001 ·The Journal of Immunology ·Delphine Réa, Menzo Havenga, (unknown), Roger P.M. Sutmuller, Angelique A. C. Lemckert, Rob C. Hoeben, A. Bout, Cornelis J.M. Melief, Rienk Offringa	130

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact